CD4 and non-small cell lung carcinoma: showed that NSCLC patients with decreased numbers of circulating CD4+T-cells and low CD62 expression(e.g., a mediator of T-cell priming and migration to secondary lymphoid tissue), developed earlier acquired anti-PD-1 resistance, in contrast to long responders characterized by increased numbers of these CD4+T-cells in the peripheral blood (45).